Procedural Skills

• 22 years of work experience in Clinical Biochemistry, including 15 years as Head of Department of Clinical Biochemistry.
• Well-versed in various biomedical techniques ( ELISA, PCR, plasmid isolation, chromatography , electrophoresis, lymphocyte culture, microbial culture) and use of various instruments like Lipid Subfractionator, Flowcytometer/ Cell sorter, Automated electro chemiluminescent analyzer, Automated ELISA analyzer, Autoanalyzer, Densitometer,IF microscopy ,Immunotyping,LC-MSetc.

ACHIEVEMENTS OF BIOCHEMISTRY DEPARTMENT AT ILBS

Clinical Biochemistry is central to diagnostics with thousands of tests (Total tests in January-June, 2023 is 3,62,951 and Total tests done from January-December 2022 is 687,318)performed daily to guide patient’s therapy. Our lab includes testing for general chemistries ,specific proteins, hormones, vitamins, tumor markers ,therapeutic drug monitoring ,dynamic LFT, immunoglobulins, tests for antibodies of autoimmune diseases and point-of-care testing (ABG/STAT creatinine /Glucometer) and other tests for research. Our goal is to give the right result at the right time, on the right specimen, from the right patient with right result interpretation based on correct reference data, and at the right price. New services & facilities added to the department in 2022-23 are: New tests-Non-esterified fatty acid(NEFA),Ketone bodies,NF-kB,S1P,Myostatin,Glypican-3,Adiponectin, IL-10,Autoimmune liver profile ,Automated urine NGAL,EGFR,FIB-4 score, APRI score, Apo-A, Apo-B, Lp(a),Angiopoetin-2,Hepatocyte growth factor(HGF),Stromal derived factor(SDF-1),Vascular endothelial growth factor(VEGF),Granulocyte stimulating factor(G-CSF),Insulin like growth factor(IGF),NAD/NADH, Angiotensin converting enzyme (ACE) test and Inhalant allergen profile.Also there are some rare tests like the Indocyanine green retention test and Ethyl glucuronide test for detecting alcohol abuse. New Facility of  new biochemistry lab. New instruments-ELISA reader (Genex),IMMUNOASSAY analyser (Atellica from Siemens). Quality Control Symposium was held in July,2022, which was first of its kind at ILBS. A PDCC in Advanced Clinical Biochemistry Course was introduced in 2021. A project on clinical evaluation of PIVKA-II as a biomarker for the diagnosis and prognosis of hepatocellular carcinoma  in the Indian population was completed in 2022 and is due for publication. Have been playing an instrumental role in various research and public health projects for screening of liver disease in the population eg. the” Healthy Liver Healthy Delhi”project. Observer ship training to doctors and internship training for M.Tech, B.Tech and MLT course students and resident doctors  is  also given in this department. Teaching of  technicians and nurses/MSc. nursing students  is also done. In future the department proposes to acquire a state of the art equipment-LC-MS in order to make the Biochemistry lab at ILBS  an Advanced Centre for Clinical Biochemistry and Metabolic diseases in Delhi. There are some publications from the department in international journals in relation to liver and kidney diseases. The lab is NABL and NABH accredited. It has also successfully under gone Kaya Kalp and Project Prakash audits.

• Merit scholar of Delhi Government for MBBS.
• Joint Secretary of Delhi Chapter of Association of Clinical Biochemists of India (ACBI), 2008.
• Joint Organizing Secretary of the Annual Conference of ACBI – ACBICON2007.
• Member of Association of Medical Biochemists of India

• Under my leadership a well-structured organisation exists in the department of biochemistry with competent direction and management
• Have systematically organized the clinical biochemistry laboratory at ILBS and have introduced state –of –the-art methods into the diagnostic laboratory. The productivity(increased volume and variety of complex measurements) of the Biochemistry lab has been improved by judicious choice of instrumentation, automation and sophisticated information systems and the lab has become responsive to provider’s and patients’needs in terms of access, cost, and quality.
• I have incorporated informatics, advanced analytical methods, interpretation of complex data and communication of medical information in meaningful ways to physician colleagues and have also taken initiatives to promote outstanding healthcare in a fiscally responsible endeavour.
• Have been instrumental in the introduction of new knowledge, new methods and new tests  for screening for the presence of disease , diagnosis , treatment and to monitor progress in the management of diseases like total bile acids, urine NGAL, serum copper, serum and urine cortisol , cardiac markers(adrenaline, noradrenaline, NT-proBNP and aldosterone),F-actin(IIF),chronic inflammatory bowel disease , obesity markers (leptin, adiponectin and ghrelin), urinary copper, anti-TPO, cancer markers CA-242,endotoxin and free fatty acids, Alcohol abuse marker-Ethyl glucuronide, inhalant and food allergy profiles, autoimmune hepatitis profile, ENA profile,RBC-Folate,Gastrin-17,Pepsinogen I & II and ratio of Pepsinogen I: Pepsinogen II, IgG H.pylori,IL-1,6,10, Enhanced Liver Fibrosis Panel, Fructosamine, Myostatin, S1P, Cyclosporine levels, CK-18, Non-esterified fatty acid(NEFA), Ketone bodies,NF-kB,S1P,Myostatin,Glypican-3,Testosterone ,EGFR,FIB-4 score, APRI score, Apo-A, Apo-B, Lp(a),Angiopoetin-2,Hepatocyte growth factor(HGF),Stromal derived factor(SDF-1),Vascular endothelial growth factor(VEGF),Granulocyte stimulating factor(G-CSF),Insulin like growth factor(IGF),NAD/NADH, Angiotensin converting enzyme (ACE) test, Glypican 3,Urine GGT, Serum KIM-1,PIVKA-II,Serum Glutathione, Serum Growth hormone, Serum Eosinophil Peroxidase, Serum Eosinophil –Derived Neurotoxin, Serum Eosinophil Chemotactic Factor, Serum Eosinophil Cationic Protein, Serum Fatty acid binding protein etc.
• Have enhanced quality assurance through initiation of EQAS programme for immunology tests , addition of endocrinology, oncology ,immunology tests and inflammatory markers in the scope of accreditation of NABL and successfully participated in  NABL, NABH, Project Prakash and Kaya Kalp audits .
• I have added various new instruments and promoted high quality of reports.
• According to our External Quality Assurance results our lab is amongst the best in the world.
• The internal quality control of POCT like ABG and stat creatinine is maintained under my supervision.
• I have also participated in public health initiatives like ‘Healthy Liver Healthy Delhi’ project with Mylan pharmaceuticals and Hepatitis day health camps.
• Areas of interest include Hepatocellular carcinoma, AKI, Nutrition, Immunopathology, Inherited metabolic disorders, Alcohol abuse markers, transplantation biochemistry and LC-MS.
• Provided internship training to Msc, MTech and BTech students .
• Provided training in Biochemistry to DNB Ophthalmology students at the Centre for Sight, New Delhi.
• Have been Co-Supervisor in various DM/MCH/PDCC /PhD theses and projects.
• A PDCC in Advanced Clinical Biochemistry Course was introduced in 2021.
• Organized a Quality Control Symposium was held in July,2022, which was first of its kind at ILBS.

• Present research work is related to determination of the efficacy of biomarkers in identifying structural kidney damage in AKI, ACLF and decompensated cirrhosis , diastolic dysfunction in chronic liver disease and its impact on morbidity and mortality, paracentesis induced circulatory dysfunction in ACLF and decompensated cirrhotics, characterization of body composition in patients with NAFLD and its association with the known risk factors in lean and obese NAFLD , effect of virgin coconut oil on the metabolic, inflammatory and oxidative profile in patients with decompensated alcoholic liver disease, role of tumor markers in diagnosing, staging ,predicting resectability and prognosis in Ca gallbladder.

HCC, Autoimmune liver disorders, Inborn errors of metabolism, Alcohol abuse marker

• Attended ANA masterclass in December 2022 and April 2023
• Attended conference on Immunology sponsored by IFCC in October 2022
• Organized first symposium on Quality in July 2022 at ILBS.
• Trained in LC-MS, Metabolomics, Lipidomics in AIIMS in 2019
• Trained in diagnosis of autoimmune disorders and immunoflourescence microscopy in 2017,2018
• Trained in Advanced methods in Biostatistics and Hands on Practice on Medical Data using SPSS Software in ILBS in 2018.
• Presented talk on the topic” Unity Real Time-a practical approach and experience sharing “ in the Unity& EQAS Interpretation Workshop organized by Bio-Rad Laboratories(India) Pvt.Ltd.in association with Apollo Hospitals, Chennai in 2012.
• In-charge of point of care testing including ABG machines, glucometers & I-stat instrument.
• Member of Apollo Hospitals Drug & Therapeutic Committee.
• Attended annual conference of American Association of Clinical Chemists in Los Angeles in 2012
• Attended conference in Mumbai on “Assuring quality, standardization & efficiency in the Laboratory”in 2012.
• Attended conference in New Delhi “ National Conference on Latest Advancements in Laboratory  Medicine” in 2011,
• Underwent training for immunotyping  in Bangalore  in 2011.
• Underwent training for  Laboratory Quality Management & Internal Audit as per ISO 15189:2007  in Chennai in 2011.
• Attended seminar on Molecular Diagnostics in Chennai in 2010.
• Attended conference in Shanghai, China for Siemen’s Automation users meet in 2010. Attended conference in Mumbai for Association of Clinical Biochemists in 2010.
• Attended training by Siemens in Singapore for Versa Cell, Advia1800, Advia Centaur XP, Dimension & Total Lab Automation in 2009.

• Total Number of publications: 38
• Total Number of publications in 2022: 3
• Total no. of Projects as PI: 1       

Details/List of Projects: Clinical application of PIVKA –II and its combination with other markers in diagnosis and prognosis of hepatocellular carcinoma  

• 1) Sarin S, Kumar S, Thomas S, Pamecha V,Trehanpati N and Sasturkar  S.Value of   temporal and quantitative profiles of eosinophilic biomarkers in the prediction of acute cellular rejection in living donor liver transplantation (Unpublished).
• 2) Anand L, Thomas SS, Sarin SK.Intravenous lipid emulsion improves nitrogen balance with preserved hepatic and immunological functions in alcoholic liver disease. (Unpublished).
• 3) Maiwall M,Pasupuleti SSR,Hidam AK,Kumar A,Tevethia HV,Vijayraghavan R,Majumdar A,Thomas S,Mathur RP,Kumar G and Sarin SK.A randomized-controlled trial(TARGET-C) of high vs.low target mean arterial pressure in patients with cirrhosis and septic shock.J Hepatol 2023; 1-13.
• 4) Maiwall M,Pasupuleti SSR,Hidam AK,Kumar A,Tevethia HV,Vijayraghavan R,Majumdar A,Parasher A,Thomas S,Mathur RP,Kumar G and Sarin SK.A randomized-controlled trial(TARGET-C)of high versus low target mean arterial pressure in patients with cirrhosis and septic shock.J Hepatol 2023;79(28).doi:10.1016/j.jhep.2023.04.006
• 5) Jain K,Rastogi A,Thomas SS and Bihari C.Autoantibody positivity has no impact on histological parameters in nonalcoholic fatty liver diseases.J Clin Experimental Hepatolol 2023;13(5):730-735.
• 6) Maiwall M,Pasupuleti SSR,Hidam AK,Kumar A,Tevethia HV,Vijayraghavan R,Majumdar A,Parasher A,Thomas S,Mathur RP,Kumar G and Sarin SK.Maladaptive tubular repair is a harbinger of chronic kidney disease development in critically-ill cirrhosis patients admitted to intensive care unit-a prospective cohort study. J Hepatol 2022;77.S51doi:10.1016/S0168-8278(22)00510-4.
• 7) Ponnappan KT,  ParveezMQ ,  Pandey CK ,  Sharma A ,  Tandon M ,  JainV, Pandey VK,  Thomas S.Plasma neutrophil gelatinase-associated lipocalin and Interleukin-18 as predictors of acute kidney injury in renal transplant recipients: A pilot study.Saudi J Kidney Dis Transpl2021 Mar-Apr;32(2):355-363.PMID: 35017329doi:10.4103/1319-2442.335447
• 8) Rastogi A,Prasad M,Kapil U,Gupta E,Thomas SS,Bihari C and Sarin SK.Prevalence and predictors of significant liver fibrosis:a population-based cross-sectional study.J Hepatol 2022;77(S1):S119-S388.
• 9) Gautam V,Khanna R,Sood V,Biharilal B,Thomas SS,Maras JS and Alam S.Effect of intravenous albumin infusion on plasma renin activity in children with decompensated cirrhosis.J Clin Experimental Hepatol 2022;12:S83.doi:10.1016/j.jceh.2022.07.200
• 10) Maiwall R,Pasupuleti SSR,Hidam AK,Rastogi A,Thomas S,Kumar G,Kumar A and Sarin SK.Maladaptive tubular repair drives non-resolution of acute kidney injury and development of chronic kidney disease in critically ill patients with cirrhosis.J Clin Experimental Hepatol 2022;12:S1.doi:10.1016/j.jceh.2022.07.010.
• 11) Gautam V,Khanna R,Mathew B,Tripathi G,Saini AK,Sood V,Biharilal B,Thomas SS,Maras JS and Alam S.Effective albumin concentration predicts survival with native liver in cirrhotic children.J Clin Experimental Hepatol 2022;12(S80-S81).doi:10.1016/j.jceh2022.07.195.
• 12) Bajpai M, Maheshwari A, Dogra V, Kumar S,Gupta E, Kale P,Saluja V,Thomas S, Trehanpati N, Bihari C, Agarwal R, Bharti P, Shankar P, Hussain J, Chhabra K, Gupta A, Narayanan A, Agarwal S, Jain S, Bhardwaj A, Kumar G, Yadav B, Sarin S.Efficacy of convalescent plasma therapy in the patient with COVID-19: a randomised control trial (COPLA-II trial) Journal: BMJ Open Manuscript ID BMJ Open 2022;12:e055189.doi:10.1136/bmjopen-2021-055189. 
• 13) Nagappan B, Ramalingam A, Rastogi A, Dubey S, Thomas SS, Gupta E and Sarin SK. Number needed to Screen to  prevent progression of fibrosis due to Alcoholic Liver disease and Non-Alcoholic Fatty Liver Disease in primary care setting: An experience from Delhi. J Family Med Prim Care2021 Mar;10(3):1412-1418.doi: 10.4103/jfmpc.jfmpc_1441_20. Epub 2021 Apr
• 14) Lokhande T, Thomas S, Kumar G and Bajpai M .The Play of Citrate Infusion with Calcium in Plateletpheresis Donors . Indian Journal Of Hematology And Blood Transfusion 2020;37(3).doi:10.1007/s12288-020-01339-z.
• 15) Arora V,Vijayragahavan, Maiwall R, Sahney A,Thomas SS, AliR , Jain P, Kumar G and Sarin SK. Paracentesis-  induced circulatory dysfunction with modest- volume paracentesis is partly ameliorated by albumin infusion in Acute- on- Chronic Liver Failure. Hepatol2019;72(3):1043-1055.doi:10.1002/hep.31071.
• 16) Premkumar M, Rangegowda D, Vyas T, Khumuckham JS, Shasthry SM, Thomas SS, Goyal R, Kumar G and Sarin SK. Carvedilol combined with Ivabradine improves left ventricular diastolic dysfunction,clinical progression,and survival in cirrhosis.J Clin Gastroenterol 2019;54(6):561-568.doi:10.1097/MCG.000000000000001219
• 17) Patidar Y, Khisti R ,Garg L, Mukund A, Thomas SS and Sarin SK.Correlation of baseline portal pressure (HVPG) and Indocyanine green clearance (ICG) test with post TACE acute hepatic failure.  J Clin  Experimental Hepatol 2019;9(4):447-452.
• 18) Contributed to poster.Mohammed Shabir Hussain,Parul Saini,Ram Kumar,Priyanka Jain,Sherin Sarah  Thomas,Shiv Kumar Sarin and Saggere M Shastry.Characterization and identification of differentially regulated proteins may identify biomarkers for early diagnosis and prognosis.Drug-induced Liver Injury(DILI)April 18-20,2019 Tokyo under the theme of”Liver Immunology and Genetics”. 
• 19) Contributed to oral presentation Mohammed Shabir Hussain,Parul Saini,Ram Kumar,Priyanka Jain,Sherin Sarah  Thomas,Shiv Kumar Sarin and Saggere M Shastry.Differentially regulated urinary proteins and their modification status serve as noninvasive biomarker for early diagnosis and characterization of drug-induced Liver Injury.May 20-21,2019 ,Rome,Italy.
• 20) Premkumar M,Devurgowda D, Vyas T , Shasthry SM, Khumuckham JS,Goyal R, Thomas SS, Kumar G .  Left ventricular diastolic dysfunction,is associated with renal dysfunction,poor survival and low health related quality of life in  Cirrhosis.J Clin Experimental Hepatol 2018:9(3)324-333.doi:10.1016.j.jceh.2018.08.008. 
• 21) Oral presentation in APASL 2018, Thomas SS,Mishra N,Manchanda P,Goyal R,Kumar and Maiwall R.New Delhi.Total serum bile acids in cirrhosis and acute-on-chronic liver failure.
• 22) Contributed to oral presentation- Premkumar M , Devurgowda D, Vyas T, Shasthry SM, SinghJK, Thomas SS, Goyal R, Kumar G, and Sarin SK, Ivabradine in combination with carvedilol improves left ventricular diastolic dysfunction, clinical progression and survival in cirrhosis: a, prospective randomized controlled trial AASLD 2017.
• 23) Premkumar M,Devurgowda D, Vyas T , Shasthry SM,Khumuckham JS, Goyal  R, Thomas SS,   Kumar G and Sarin SK.Targeted heart rate reduction using carvedilol± ivabradine improves left ventricular diastolic dysfunction,clinical progression and survival in cirrhosis- an interim report.AASLD7/11/16.
• 24) Thomas SS. LDL Subfractions:  A breakthrough in cholesterol testing. Fortis  Medical Journal 2009:1(3); 15-17.
• 25) Raizada A, Bhandari S, Khan MA, Singh HV, Thomas SS, Sarabhai V, Singh N, Trehan N. “Brain type natriuretic peptide  ( BNP )”-A marker of the new millennium in diagnosis of congestive heart failure. Indian J Clin Biochemistry 2007;22 (1):4-9.
• 26) Selected for poster presentation entitled “Low density lipoprotein ( LDL ) subfractions in Indians” on October 14-20, 2007 at a Conference of the Asia-Pacific Congress of Clinical Chemistry at Beijing, China.
• 27) Selected for poster presentation entitled “Low density lipoprotein ( LDL ) subfractions in Indians” on June 4,2007 at EUROMEDLAB 2007 at Amsterdam, Netherlands.
• 28) Oral presentation“LDL  subfractions in Indians” February 22, 2007 at Goa Medical College, Goa.
• 29) Oral presentation “LDL subfractions in Indians” November 26, 2006 at 33^rd ACBICON,2006 at AFMC, Pune.
• 30) Contributed to oral presentation-“Serum apolipoproteins A-I, A-II,B,C-II,C-III, E and Total Antioxidant Status in angiographically proved CAD cases” at an International Conference at Bangalore ( January 12,2005 ). Abstract no.OL-30, pp 76 in the Proceedings of the conference.
• 31) Presented poster entitled “Inflammatory markers in coronary artery disease” at an International Conference on Antioxidants & Free Radicals in Health – Nutrition & Radio-protectors at Bangalore (January 12, 2005). Abstract no. P- 192, pp 164 in the Proceedings of the conference.
• 32) Thomas SS. Current topics in computational molecular biology. Anil Aggrawal’s Internet Journal of Book Reviews 2004; 3(1): 1
• 33) Thomas SS. Electron paramagnetic resonance in biochemistry and medicine. Anil Aggrawal’s Internet Journal of  Forensic Medicine and Toxicology 2004; 5(1):1
• 34) Thomas SS, Chhabra SK. A study on the serum levels of interleukin-1β in bronchial asthma. Journal of the Indian Medical Association 2003; 101(5): 282-84,286,288.
• 35) Thomas SS, Aggrawal KK. Methylcobalamin: The real Vitamin B12. Indian Journal of Clinical Practice Publication 2003.
• 36) Thomas SS. Exploratory analysis and data modelling in functional neuroimaging. Anil Aggrawal’s Internet Journal of Book Reviews 2003; 2(2): 2. NLM Unique  ID of the Journal:100960452
• 37) Thomas SS. The handbook of  brain theory and neural networks. Anil Aggrawal’s Internet Journal of  Book Reviews 2003; 2(2): 3
• 38) Thomas SS, Chhabra SK. A study on the serum levels of interleukin-1β in bronchial asthma. Journal of the Indian Medical Association 2003; 101(5): 282 - 84,286,288.